Highlights AstraZeneca Pharma India Limited

Equities

506820

INE203A01020

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-06-25 EDT			5-day change	1st Jan Change
6,320 ^INR	+0.01%		-1.80%	+14.49%

06-21	AstraZeneca Pharma Fails to Find Buyer for Manufacturing Site in Bangalore, India	MT
06-01	Astrazeneca Pharma India Limited Appoints Shikha Mirchandani Chatrath as Director - Commercial Excellence, BD & Strategy, Effective June 17, 2024	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Astrazeneca Pharma India's Net Profit Rises in Fiscal Q4	05-28	MT
Astrazeneca Pharma India Limited Recommends Dividend for the Financial Year 2023-24	05-27	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-27	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-27	CI
Astrazeneca Pharma India Limited Provides Update on Olaparib 100mg and 150 mg Tablets	05-21	CI
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India	03-11	MT
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India	03-11	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-08	CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion	01-21	MT
Astrazeneca Pharma to Launch Breast Cancer Treatment Drug in India in January 2024	12-21	MT
AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
AstraZeneca Gets Indian Drug Regulator's Nod to Import Pharmaceutical Formulations for Palivizumab	23-10-02	MT
Astrazeneca Pharma India Limited Receives Permission to Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab	23-09-30	CI
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023	23-08-17	CI
AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
AstraZeneca Pharma Launches Neurofibromatosis Type 1 Drug in India	23-08-10	MT
AstraZeneca Pharma India Limited Announces Launch of Selumetinib 10 Mg and 25 Mg Capsule	23-08-09	CI
AstraZeneca Pharma India Limited Proposes to Declare Dividend for the Financial Year 2022-23	23-07-22	CI
Ex-dividend day for final dividend	23-07-13	FA
AstraZeneca Gets Regulatory Nod to Import Tremelimumab (Imjudo) Concentrate	23-06-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AstraZeneca Pharma India Limited

Equities

506820

INE203A01020

Highlights

Filters